Monoterpenoid Epoxidiol Ameliorates the Pathological Phenotypes of the Rotenone-Induced Parkinson's Disease Model by Alleviating Mitochondrial Dysfunction.

Abstract

Parkinson's disease is the second most common neurodegenerative disease. Unfortunately, there is still no definitive disease-modifying therapy. In our work, the antiparkinsonian potential of trans-epoxide (1S,2S,3R,4S,6R)-1-methyl-4-(prop-1-en-2-yl)-7-oxabicyclo [4.1.0]heptan-2,3-diol (E-diol) was analyzed in a rotenone-induced neurotoxicity model using in vitro, in vivo and ex vivo approaches. It was conducted as part of the study of the mitoprotective properties of the compound. E-diol has been shown to have cytoprotective properties in the SH-SY5Y cell line exposed to rotenone, which is associated with its ability to prevent the loss of mitochondrial membrane potential and restore the oxygen consumption rate after inhibition of the complex I function. Under the conditions of rotenone modeling of Parkinson's disease in vivo, treatment with E-diol led to the leveling of both motor and non-motor disorders. The post-mortem analysis of brain samples from these animals demonstrated the ability of E-diol to prevent the loss of dopaminergic neurons. Moreover, that substance restored functioning of the mitochondrial respiratory chain complexes and significantly reduced the production of reactive oxygen species, preventing oxidative damage. Thus, E-diol can be considered as a new potential agent for the treatment of Parkinson's disease.

• Authors: Yulia Aleksandrova, Kirill Chaprov, Alexandra Podturkina, Oleg Ardashov, Ekaterina Yandulova, Konstantin Volcho, Nariman Salakhutdinov, Margarita Neganova
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 24 Issue 6 (Mar 19 2023) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 36982914 (Publication Type: Journal Article)

Chemical References

• Rotenone
• Monoterpenes
• Reactive Oxygen Species
• Neuroprotective Agents

Topics

• Animals
• Humans
• Parkinson Disease (drug therapy, etiology, metabolism)
• Rotenone (toxicity, metabolism)
• Monoterpenes (metabolism)
• Neurodegenerative Diseases (metabolism)
• Cell Line, Tumor
• Neuroblastoma (metabolism)
• Reactive Oxygen Species (metabolism)
• Mitochondria (metabolism)
• Phenotype
• Neuroprotective Agents (pharmacology, therapeutic use, metabolism)